See more : A2A S.p.A. (A2A.MI) Income Statement Analysis – Financial Results
Complete financial analysis of DICE Therapeutics, Inc. (DICE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DICE Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Paragon Technologies Co., Ltd. (3518.TW) Income Statement Analysis – Financial Results
- Porn Prom Metal Public Company Limited (PPM.BK) Income Statement Analysis – Financial Results
- LKP Finance Limited (LKPFIN.BO) Income Statement Analysis – Financial Results
- GP-Act III Acquisition Corp. Warrants (GPATW) Income Statement Analysis – Financial Results
- Erste Group Bank AG (EBS.VI) Income Statement Analysis – Financial Results
DICE Therapeutics, Inc. (DICE)
About DICE Therapeutics, Inc.
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 1.13M | 863.00K | 5.78M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 1.13M | 863.00K | 5.78M |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 62.56M | 36.51M | 19.58M | 15.72M |
| General & Administrative | 25.66M | 12.22M | 5.00M | 3.61M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.66M | 12.22M | 5.00M | 3.61M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 88.22M | 48.73M | 24.58M | 19.32M |
| Cost & Expenses | 88.22M | 48.73M | 24.58M | 19.32M |
| Interest Income | 5.21M | 136.00K | 139.00K | 635.00K |
| Interest Expense | 679.00K | 174.00K | 13.00K | 26.00K |
| Depreciation & Amortization | 5.21M | 136.00K | 836.00K | 1.34M |
| EBITDA | -83.01M | -47.47M | -22.89M | -12.21M |
| EBITDA Ratio | 0.00% | -4,219.29% | -2,651.80% | -211.36% |
| Operating Income | -88.22M | -47.60M | -23.72M | -13.55M |
| Operating Income Ratio | 0.00% | -4,231.38% | -2,748.67% | -234.58% |
| Total Other Income/Expenses | 4.33M | -1.36M | -18.00K | 609.00K |
| Income Before Tax | -83.89M | -48.96M | -23.74M | -12.94M |
| Income Before Tax Ratio | 0.00% | -4,351.91% | -2,750.75% | -224.03% |
| Income Tax Expense | -2.22M | -487.00K | 13.00K | 26.00K |
| Net Income | -81.66M | -48.47M | -23.75M | -12.96M |
| Net Income Ratio | 0.00% | -4,308.62% | -2,752.26% | -224.48% |
| EPS | -2.07 | -3.91 | -1.02 | -0.56 |
| EPS Diluted | -2.07 | -3.91 | -1.02 | -0.56 |
| Weighted Avg Shares Out | 39.40M | 12.38M | 23.23M | 23.23M |
| Weighted Avg Shares Out (Dil) | 39.40M | 12.38M | 23.23M | 23.23M |
Is DICE Therapeutics (DICE) Outperforming Other Medical Stocks This Year?
These 3 Stocks Are Crushing the Market. Wall Street Thinks They Can Soar at Least 78% Higher.
DICE Therapeutics to Present at Upcoming Investor Conferences
DICE Therapeutics: Moving Things Along Nicely
DICE Therapeutics (DICE) Up on Top-Line Data From Psoriasis Study
Nasdaq Bear Market: 2 Stocks Defying the Downturn
Dice Therapeutics Surges To Record High As Psoriasis Pill Promises To Lead Its Class
Why Earnings Season Could Be Great for DICE Therapeutics (DICE)
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
DICE Therapeutics to Present at the 2022 Jefferies Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports